Condition
T-cell Large Granular Lymphocytic Leukemia
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05532722Phase 1CompletedPrimary
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
NCT05978141Recruiting
A Registry for People With T-cell Lymphoma
NCT00076180Phase 1CompletedPrimary
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
NCT02742727Phase 1Unknown
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
NCT00278265Phase 2TerminatedPrimary
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
Showing all 5 trials